Company news
Vistagen Therapeutics, Inc. (NASDAQ:VTGN) news
Vistagen Therapeutics, Inc. news releases on 6ix. Latest, Sep 24, 2026: Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe…
Press releases & updates
Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorder
September 24, 2026
Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
September 22, 2026
Vistagen to Present at Psych Congress 2026
September 10, 2026
Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update
August 14, 2026
Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
August 6, 2026
SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN)
August 4, 2026
Vistagen Appoints Douglas J. Williamson to its Board of Directors
July 31, 2026
Vantage : Annual Report for Fiscal Year Ending March 31, 2026 (Form 20-F)
July 27, 2026
Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder
June 30, 2026
Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
June 15, 2026
Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder
June 9, 2026
Vistagen to Participate in Jefferies 2026 Global Healthcare Conference
May 27, 2026
Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer
May 18, 2026
Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
May 12, 2026
Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
May 8, 2026
Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause
April 21, 2026
Vistagen to Participate in Upcoming Investor Conferences
March 3, 2026
Vistagen to Participate in the 46th Annual TD Cowen Healthcare Conference
February 25, 2026
Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update
February 12, 2026
Vistagen to Report Fiscal Year 2026 Third Quarter Results and Host Corporate Update Conference Call on February 12, 2026
February 4, 2026
Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
December 17, 2025
Vistagen Appoints Nick Tressler as Chief Financial Officer
December 1, 2025
Vistagen Reports Findings on PH80’s Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting
November 26, 2025
Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update
November 13, 2025
Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025
November 10, 2025
Vistagen to Participate in Stifel Healthcare Conference 2025
November 5, 2025
Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder
November 3, 2025
Vistagen Appoints Paul Edick to its Board of Directors
October 29, 2025
Vistagen to Present at The Menopause Society 2025 Annual Meeting
October 16, 2025
Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
September 9, 2025
Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update
August 7, 2025
Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025
July 31, 2025
Vistagen to Present at the BTIG Virtual Biotechnology Conference
July 24, 2025
Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership
July 15, 2025
Vistagen Appoints Elissa Cote as Chief Corporate Development Officer
June 25, 2025
Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update
June 17, 2025
Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025
June 12, 2025
Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year
June 2, 2025
Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York
May 28, 2025
Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference
May 23, 2025
Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference
April 17, 2025
Vistagen to Present at the 2025 Anxiety and Depression Association Conference
March 19, 2025
Vistagen to Participate in Stifel 2025 Virtual CNS Forum
March 4, 2025
Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference
February 20, 2025
Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update
February 12, 2025
Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain
February 4, 2025
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia
January 13, 2025
Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder
January 9, 2025
Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update
November 6, 2024
Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
September 22, 2024